Announcements

Daniel Brignardello, Executive Vice President of EVERTEC, Inc., filed a Form 4 on November 9, 2026, disclosing a disposition of 1,880 shares of common stock on November 5, 2026, related to the vesting of restricted stock units.

Orchestra BioMed Holdings, Inc. filed a Form 8-K on November 9, 2026, disclosing the entry into an underwriting agreement and the closing of an underwritten public offering of common stock that generated approximately $86.3 million in gross proceeds.

Andrew Lawrence Taylor, Chief Financial Officer of Orchestra BioMed Holdings, Inc., filed a Form 4 on November 9, 2026, disclosing the purchase of 1,000 shares of common stock at $5.00 per share in an underwritten public offering.

David P. Hochman, Chief Executive Officer and Chairperson of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO), filed a Form 4 on November 9, 2026, disclosing the purchase of 5,000 shares of common stock in an underwritten public offering at $5.00 per share.

Director David Pacitti filed a Form 4 with the SEC on November 9, 2026, disclosing the purchase of 20,000 shares of Orchestra BioMed Holdings, Inc. common stock at $5.00 per share in an underwritten public offering.

Director Eric S. Fain filed a Form 4 with the SEC on November 9, 2026, disclosing a purchase of 20,000 shares of Orchestra BioMed Holdings, Inc. common stock at $5.00 per share through an underwritten public offering.

Michael Gunnar Knell, SVP, Finance and Chief Accounting Officer of Charles River Laboratories International, Inc., filed a Form 4 on November 9, 2026, disclosing a disposition of 649 shares of common stock on November 6, 2026, to satisfy tax withholding obligations tied to the …